PharmaBlock is delighted to announce the recent appointment of Dr. David (Zhihong) Chen as Chief Operating Officer and Head of CDMO Business. Dr. Chen brings over 30 years of extensive experience in pharmaceutical development, particularly in quality management and GMP manufacturing. Before his formal appointment as COO and Head of CDMO Business, he has been the Chief Strategic Consultant at PharmaBlock since last October.

Throughout his distinguished career, Dr. Chen has held numerous leadership roles, including President and VP of Quality at Zhejiang Jiuzhou Pharma, VP of Quality at Shanghai Desano Pharma, and Director of Quality and Regulatory Compliance at Roche R&D Center (China). He co-founded Pharmalytica Services, a CRO specializing in analytical services, and has held significant positions at Schering-Plough and Roche Pharmaceuticals in the USA. Dr. Chen has overseen more than 50 regulatory inspections from agencies such as CFDA, FDA, EDQM, and WHO, underscoring his expertise in compliance and quality assurance.

PharmaBlock is renowned for its excellence in chemistry and low-carbon technology innovation. In recent years, the company has delivered numerous challenging molecules to global partners, from early development to commercial stage. With Dr. Chen joining our team, we are confident that his profound understanding and hands-on experience in quality management and GMP manufacturing will greatly enhance our delivery quality, especially in late-stage development and commercial manufacturing. His leadership will be instrumental in ensuring the seamless progression of our customers' projects through these critical phases.

We eagerly anticipate the significant advancements Dr. Chen will bring to our organization and the ongoing success of our clients.

Learn more about PharmaBlock Core Team of CDMO Business